Repatha Cost in Texas 2026: Prices, Insurance, Medicaid, and Compounding Options

What Is the List Price of Repatha in Texas in 2026?

Amgen's wholesale acquisition cost (WAC) for Repatha in 2026 sits at approximately $580 per month, regardless of which Texas pharmacy dispenses it. That figure applies to both the 140 mg/mL single-use prefilled autoinjector (used every two weeks) and the 420 mg/3.5 mL monthly SureClick device. Cash-pay patients who present no insurance or copay card will typically see a retail price at that WAC level, occasionally plus a dispensing fee. The FDA-approved prescribing information for evolocumab confirms the two approved dosing regimens that determine monthly supply quantities.

WAC is not always what patients pay. Pharmacy benefit managers negotiate rebates that can reduce net cost substantially, but those savings rarely pass through to cash-paying individuals. Texas has no state-level drug price transparency law that forces pharmacies to post a standardized price, so quotes can vary by $10 to $30 between chains such as CVS, Walgreens, H-E-B, and Costco. Calling each pharmacy's specialty-drug line with the GoodRx or NeedyMeds coupon code in hand is the fastest way to find the lowest local price before any manufacturer assistance is applied.

For context on why the price is so high: evolocumab is a fully human monoclonal antibody that inhibits PCSK9, allowing LDL receptors to recycle and clear more LDL-C from circulation. FOURIER (N=27,564) demonstrated a 59% reduction in LDL-C from baseline and a 15% relative reduction in the composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization over a median 2.2 years. That clinical profile supports the premium pricing, but it does not make the drug affordable for uninsured Texans without assistance programs.

How Does the Amgen SupportPlus Savings Card Work in Texas?

Commercially insured Texans who are not on a government program pay as little as $0 per month through the Amgen Repatha SupportPlus copay card. The card caps out-of-pocket cost at a maximum of $10 per 30-day supply for eligible patients, and Amgen covers the rest of the commercially negotiated cost. Enrollment takes about five minutes at Amgen's website and requires proof of commercial insurance (Medicare, Medicaid, CHIP, and other federal programs are excluded by federal anti-kickback rules).

The savings card works at virtually every retail and specialty pharmacy in Texas that stocks Repatha, including CVS Specialty, Walgreens Specialty, and Baylor Scott and White specialty pharmacy. A prescription is still required. The prescriber can be a cardiologist, primary care physician, or a telehealth provider licensed in Texas. Once enrolled, the card auto-renews annually and patients receive a reminder before it expires.

Income-based patients who do not have commercial insurance and do not qualify for Medicare can apply to the Amgen Safety Net Foundation, which provides free drug to qualifying households. Eligibility in 2026 is set at household income at or below 500% of the federal poverty level. Texas ranks among the top five states by number of uninsured adults nationally, according to CDC data on state-level uninsured rates, so this pathway matters for a meaningful subset of patients seeking PCSK9 inhibitor therapy.

A third track is the NeedyMeds database, which aggregates state-specific patient assistance programs. Texans who do not qualify for the Amgen Safety Net Foundation because they earn slightly above the threshold may find bridge grants through hospital charity care or local health plans. The American Heart Association's guidance on PCSK9 inhibitor access barriers specifically names cost as the primary driver of under-utilization of this drug class, with fewer than 30% of eligible patients ever filling a first prescription.

Does Texas Medicaid Cover Repatha?

Texas Medicaid does not cover Repatha for atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) indications in 2026. Coverage under STAR and STAR+PLUS managed care plans is restricted to patients with type 2 diabetes who meet specific glycemic and cardiovascular risk criteria, and even that pathway requires prior authorization with step-therapy documentation showing statin failure or intolerance. The Texas Medicaid and CHIP formulary guidance aligns with state Vendor Drug Program criteria published by the Texas Health and Human Services Commission.

This coverage gap affects a large number of Texans. The ACC/AHA 2022 Guideline on Atherosclerotic Cardiovascular Risk recommends PCSK9 inhibitors for patients with established ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy. Texas has an estimated 2.7 million adults with established ASCVD. A large proportion are enrolled in Medicaid or are uninsured, and the current formulary position leaves them without a realistic path to this drug class through the public payer.

Medicaid managed care organizations in Texas (Molina, BCBS of Texas Medicaid, United Healthcare Community Plan, and Superior Health Plan) each maintain their own preferred drug lists (PDLs) within the state Vendor Drug Program framework. None of these plans listed Repatha for ASCVD on their 2026 PDLs as of this writing. Prior authorization requests for off-label Medicaid coverage can be filed and are occasionally approved on clinical exception; documentation should include recent lipid panels, a full statin trial history, and a letter of medical necessity from a cardiologist or lipidologist.

Which Private Insurance Plans in Texas Cover Repatha?

Most large commercial insurance plans operating in Texas do cover Repatha, but almost all require prior authorization (PA) and step therapy. The most common PA criteria across Blue Cross Blue Shield of Texas, Aetna, Cigna, and UnitedHealthcare are: (1) an LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy, (2) a diagnosis of heterozygous or homozygous FH or established ASCVD, and (3) documentation of a trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days. The ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction published in JACC provides the clinical framework most Texas payers use to design their PA criteria.

Step therapy requirements often include a documented trial of ezetimibe 10 mg daily for 90 days before a PCSK9 inhibitor is approved. Patients who are statin-intolerant must provide documentation of myopathy, myalgia, or elevated CK on at least two different statins. Telehealth providers in Texas can generate this documentation and submit PA requests electronically, which has meaningfully reduced the time from prescription to first fill.

Texas-based employer self-insured plans (governed by ERISA rather than state insurance law) sometimes have narrower formularies that exclude Repatha even when the state-regulated individual market plans cover it. Employees should request a formulary exception through HR or their PBM directly. A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that PA approval rates for PCSK9 inhibitors ranged from 41% to 79% across commercial payers, with denial most common when LDL-C documentation was incomplete.

Is Compounded Evolocumab Legal in Texas?

Compounded evolocumab from a licensed 503A pharmacy is legal in Texas. A 503A pharmacy compounds for individual patients under a valid prescriber-patient relationship, operating under oversight from the Texas State Board of Pharmacy (TSBP) and subject to USP Chapter 797 sterile compounding standards. No 503B outsourcing facility may compound evolocumab unless FDA places the active pharmaceutical ingredient on the 503B bulks list, which has not occurred as of mid-2025.

The legality question is real. Evolocumab is a branded biologic, not a small-molecule drug. Compounding a biologic from raw active pharmaceutical ingredient (API) raises regulatory questions that 503A pharmacies manage carefully. The FDA's guidance on compounding biologics notes that while Section 503A of the Federal Food, Drug, and Cosmetic Act does not categorically exclude biologics, FDA exercises enforcement discretion on a case-by-case basis. Patients considering this pathway should ask the compounding pharmacy directly for its TSBP license number, its most recent USP 797 compliance inspection date, and the source and certificate of analysis for its evolocumab API.

Cost is the primary driver of interest in compounded evolocumab. Cash prices at licensed Texas 503A pharmacies vary, but several are currently offering formulations at substantially below the Amgen WAC. Some clinics report prices in the range of $100 to $200 per month for compounded PCSK9 inhibitor formulations, though these prices are not standardized and can change with API availability.

The clinical efficacy of compounded evolocumab has not been validated in a controlled trial the way branded Repatha was in FOURIER. The FOURIER trial enrolled 27,564 patients with established cardiovascular disease and statin therapy, found a 59% LDL-C reduction with evolocumab versus placebo, and showed a hazard ratio of 0.85 (95% CI 0.79 to 0.92, P<0.001) for the primary endpoint NEJM 2017. That data was generated using Amgen's biologic manufacturing process. Compounded preparations may differ in folding, aggregation, or immunogenicity, and no head-to-head bioequivalence study exists for compounded versus branded evolocumab.

Prescribers who order compounded evolocumab in Texas should document the clinical rationale, confirm pharmacy credentials, and monitor LDL-C at 4 to 8 weeks after initiation to verify the expected response. A repeat LDL-C reduction of at least 40% from baseline on a statin background suggests adequate biologic activity. Failure to achieve that threshold warrants a switch to branded Repatha or another validated PCSK9 inhibitor.

Can a Texas Telehealth Provider Prescribe Repatha?

Yes. Texas telehealth law permits a licensed Texas physician, nurse practitioner, or physician assistant to prescribe Repatha via a synchronous video visit after establishing a valid patient-provider relationship. The Texas Medical Board and the Texas State Board of Pharmacy both recognize telemedicine-initiated prescriptions for specialty medications including biologics and injectable drugs.

The Texas Telehealth Improvement Act (HB 1063, 2017) established parity for telehealth prescribing of medications that do not fall under DEA controlled substance restrictions. Repatha is not a controlled substance, so no in-person visit is required before a Texas telehealth provider writes the first prescription. The provider must still collect a sufficient clinical history, review relevant labs (lipid panel within 12 months, hepatic function, CK if statin intolerance is a factor), and document the indication.

Telehealth platforms that serve Texas patients can initiate the prior authorization process electronically on the patient's behalf, often shortening the time from initial consultation to first fill to under two weeks. Patients who have been denied PA through their primary care physician's office sometimes find that a telehealth lipidology consultation generates more detailed documentation that reverses the denial.

What Is the Cheapest Way to Get Repatha in Texas in 2026?

The cheapest path depends on insurance status. Four scenarios cover most Texas patients.

Commercially insured with a non-government plan: use the Amgen SupportPlus savings card, which caps cost at $0 to $10 per month. This is the most common scenario and the lowest-cost option for the majority of working-age Texans.

Medicare Part D: the Inflation Reduction Act's $2,000 annual out-of-pocket cap applies in 2026, and the Medicare Extra Help (Low Income Subsidy) program reduces costs further for qualifying patients. CMS guidance on Part D redesign for 2025 and 2026 covers the details. Patients should compare plans during open enrollment to find the plan with the lowest Repatha tier.

Uninsured and low-income: apply to the Amgen Safety Net Foundation for free drug. NeedyMeds.org maintains current income thresholds and application links.

Uninsured and higher income, or Medicaid patient without coverage: consider compounded evolocumab from a licensed Texas 503A pharmacy, with the caveats about efficacy monitoring described above.

The ACC/AHA cholesterol guideline recommends a 50% or greater LDL-C reduction in very high-risk ASCVD patients, and a baseline LDL-C above 70 mg/dL on maximally tolerated statin therapy is the accepted threshold for adding a PCSK9 inhibitor. Getting that reduction affordably is a solvable problem for most Texans with the right assistance pathway.

Monitoring and Clinical Expectations After Starting Repatha

Starting evolocumab requires a baseline lipid panel and a follow-up panel 4 to 8 weeks after the first injection. The 2022 ACC/AHA guideline update on non-statin therapies recommends confirming LDL-C response at that interval and then annually if the patient is stable. Patients on the 140 mg every-two-weeks regimen inject subcutaneously into the abdomen, thigh, or upper arm, rotating sites to minimize local reactions.

The most common adverse effects reported in FOURIER were nasopharyngitis (10.5% evolocumab vs. 10.3% placebo), upper respiratory tract infection, and injection-site reactions occurring in 2.1% of patients. The full safety data are published in the NEJM FOURIER paper. Neurocognitive adverse events were assessed in the EBBINGHAUS sub-study (N=1,204), which found no significant difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery after a median follow-up of 19 months, as published in NEJM 2017.

LDL-C goals after starting therapy depend on risk category. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends an LDL-C target of <70 mg/dL for very high-risk ASCVD and <55 mg/dL for patients with recurrent events. Texas cardiologists and primary care physicians using HealthRX telehealth services typically order a comprehensive metabolic panel alongside the lipid panel at the 4-to-8-week visit to confirm no unexpected hepatic changes, though evolocumab has no hepatotoxicity signal in clinical trials.

Patients who self-inject should store Repatha prefilled pens at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) in the original carton and may store at room temperature (below 77 degrees Fahrenheit) for up to 30 days. Texas summer temperatures can exceed safe storage ranges rapidly, so patients should avoid leaving the medication in a vehicle or uninsulated bag. FDA labeling provides full storage requirements.

Prior Authorization Strategy for Texas Patients

Prior authorization denial is the single largest barrier to access. A well-prepared PA request addresses four elements: diagnosis documentation (ICD-10 code for ASCVD or FH), lab evidence (LDL-C value and date on maximally tolerated statin), statin trial history (drug name, dose, duration, reason for discontinuation if applicable), and a letter of medical necessity signed by the treating physician.

Texas insurance law requires a decision on standard PA requests within 3 business days and urgent PA requests within 1 business day under TDI rules. If a PA is denied, a peer-to-peer call between the prescribing physician and the payer's medical director resolves the denial in roughly 70% of cases when the clinical documentation is complete, according to a 2021 review in Circulation: Cardiovascular Quality and Outcomes. An appeal following a peer-to-peer denial can be filed and escalated to an independent review organization (IRO) if the appeal is also denied. Texas law requires the IRO to issue a decision within 30 days for standard appeals.

Patients who have experienced a major adverse cardiovascular event (MACE) within the past 12 months may qualify for a medical emergency exception under some Texas commercial plans, allowing a 30-day bridge supply while the full PA is processed. Confirm this option with the pharmacy and the payer before the prescription is submitted.

A 2023 JAMA Internal Medicine analysis of PCSK9 inhibitor PA denials found that 43% of initial denials were overturned on first appeal when complete LDL-C documentation was provided, reinforcing the value of thorough medical records from the outset.